SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Zonagen (zona) - good buy?
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Linda Kaplan who wrote (6495)5/8/1999 12:04:00 AM
From: VLAD  Read Replies (1) of 7041
 
FWIW,

I just spoke to a friend that claims:

1)the FDA one week ago told SGP that it needed to provide some important safety data regarding Vasomax and unless the information was not received in 2 weeks, consideration for approval would be pushed forward by one year.

2)As of today the FDA has still not received the information.

3)Apparently the FDA was not impressed with the difference between the success rate of placebo vs Vasomax and seeing that the difference was only 13% they are seriously going to scrutinize the safety data. Also, consider the fact that the FDA is still in the hot seat regarding the Viagra safety issues.

I do not know if any of this information is fact or just unsubstantiated rumor. But if it is fact and SGP doesn't cough up the requested safety data and the FDA requires more clinical studies to determine safety issues, IMO we will see single digits REAL fast.

Has any body heard any information related to this?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News